ClinicalTrials.gg
RecruitingNCT06582199BioCogBank-ADUpdated Mar 27, 2026

Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD

An interventional study of Blood sample and Neuropsychological battery tests in Alzheimer Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
244
Allocation
Not applicable
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, 1 of them phase 3. Alzheimer Disease · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
2nd of 14
244 · median 91
Started
2024
with 2 others
No phase
11 of 28
4 open now
Registered
25th of 28
by date

Among the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 with no phase, and was the 25th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

9 of the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

BioCogBankAD aims at building a prospective clinical practice cohort of 244 patients with biologically confirmed mild cognitive impairment due to Alzheimer's Disease (AD) or mild AD in order to validate data regarding markers of resilience toward AD pathophysiological process discovered in an upstream project called AD-Resilience.

Read the detailed description

Alzheimer's disease (AD) is a leading cause for individual and caregiver burden associated with neurodegenerative diseases (NDs) in an aging population, afflicting + 35 million people worldwide, and spiraling costs. Major advances have been made during the last 20 years in the understanding of AD pathophysiological process. It is now well demonstrated that the course of the disease extend over more than 20 years with long pre and pauci-symptomatic periods.

A major need and challenge in translational research on Alzheimer's disease (AD) is to predict disease progression rate and/or time to clinical conversion, notably in the early phases of the AD process, such as mild cognitive impairment (MCI). Current markers such as Aß and tau species measured in cerebrospinal fluid (CSF) can differentiate AD from control and are currently used in daily clinical practice to assess presence of AD pathological process in patients with cognitive complaints. However, they do not account for cellular compensation and resistance mechanisms, the so-called "resilience" process.

Consequently, both prediction of AD progression in single patients and personalized adaptation of management and treatment remain highly limited. Moreover, there is an important unmet need regarding targeted prevention.

AD-Resilience is a translational research study funded by Agence Nationale pour la Recherche (ANR) and Direction Générale de l'Organisation des Soins (DGOS) that aims at identifying and validating markers of the biological processes underlying the mechanisms of brain resilience toward AD pathological process. Using blood samples, the investigators will produce the molecular-profile data that are needed to assess the resilience and brain homeostasis status of patients facing the AD process. Results will be processed using high-end machine learning (ML) to overcome the limitations associated with sub-optimal reliability and precision of dimensional data analysis.

These biomarkers will be identified using data and samples from an already available nationwide research cohort (BALTAZAR). In order to ensure validity and facilitate transfer to clinical practice, results from this preliminary study will have to be confirmed in an independent, prospective cohort of patients reflecting the full spectrum and real-life heterogeneity of AD.

For this purpose, BioCogBankAD study aims at building this validation cohort. 244 patients with MCI or early dementia due to AD will be recruited in the present study and prospectively followed during three years. Blood samples (plasma, DNA and PaxGen) will be taken from these patients in order to measure the biomarkers previously identified in the exploratory study. Clinical follow-up including including standardized neuropsychological examination and blood sampling (plasma) will be performed annually.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Alzheimer Disease
  • Mild cognitive impairment
  • Resilience
  • Biomarkers
  • Cohort
  • Clinical practice
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AD according to IWG-2 2014 criteria
  • Age 50-90 year old
  • Affiliated or beneficiary of a social security scheme
  • ≥ 20
  • Abnormal CSF Aβ42 or Aβ40/Aβ42 ratio according to local cut-offs
  • Abnormal CSF phosphorylated and total Tau according to local cut-offs
  • Ability to pass neuropsychological assessments
  • Availability of a brain MRI with T1 volumetric sequence performed within 1 year

Exclusion criteria

Exclusion Criteria:

  • Other cause of dementia
  • Participation in an AD therapeutic clinical trial
  • Protected adults (including individual under guardianship by court order),
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
244 participants (estimated)

Study arms

  • Experimental
    Exploratory group

    Other: Blood sample · Behavioral: Neuropsychological battery tests

Interventions

  • OtherBlood sample

    Plasma, DNA, RNA and PBMC Sampling

  • BehavioralNeuropsychological battery tests

    * Short term memory: Digit span (forward and backward) * Long term memory: Free and Cued selective reminding Test * Language and semantic Memory : Verbal Fluency (Category and Litteral), Image Naming (DO 40) * Praxis * Visuo Spatial abilities: Rey-Osterrieth Complex Figure Test * Attention and executive functions: Trail Making Test (TMT) Part A and B, Frontal Assessment Battery (FAB) * Autonomy in daily life activities : Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL), Instrumental Activities of Daily Living (IADL) * Mood and anxiety: Hospital Anxiety and Depression Scale (HADS) * Cognitive reserve : Cognitive Reserve Index questionnaire (CRIq)

06

What researchers measure

Primary outcomes

  1. Mean levels of new blood biomarkers

    assess biomarkers of biological resilience toward AD pathological process

    Time frame: 36 months

Secondary outcomes

  1. Mini-Mental State examination (MMSE)

    assess relationship between new biomarkers (biomarkers identified in the current study on the analysis of study samples Baltazar) and cognitive decline - MMSE: 0 to 30 evaluates memory, orientation in space and time, learning and immediate memory, attention and reasoning, language and ability to perform tasks. * Score of 27 or more: no cognitive impairment * Score between 21 and 26: slight impairment * Score between 11 and 20: moderate impairment * Score below 10: severe impairment

    Time frame: 36 months

  2. Cognitive performance (zScore)

    assess relationship between new biomarkers (biomarkers identified in the current study on the analysis of study samples Baltazar) and cognitive decline -

    Time frame: 36 months

  3. Instrumental Activities of Daily Living (IADL)

    assess relationship between new biomarkers and loss of autonomy (decline on IADL) - 0 dependent to 17 Assessment of autonomy in instrumental activities of daily living - The score shows the level of autonomy: a maximum score represents maximum autonomy, and the lower the score, the lower the level of autonomy.

    Time frame: 36 months

  4. Hospital Anxiety and Depression Scale (HADS)

    The HAD scale is a screening instrument for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven to depression (total D), giving two scores (maximum score for each = 21). 0 = no anxiety 21= anxiety and depressive disorders max

    Time frame: 36 months

  5. Cognitive Reserve Index questionnaire (CRIq)

    CRI schooling min = 0 no schooling, training or internship - Max = undefined because "+1" corresponds to each year of schooling and +0.5 for any internship of more than 6 months - CRI work is the number of years of work, rounded to a scale of 5 (0-5-10-15-20) to assess the degree of intellectual effort and personal responsibility - CRI leisure from never/rarely to often/always (checkboxes) multiplied by number of years of practice. Score CRI : * ≤70 = low * 70 to 84 = low average * 85 to 114 = average From 115 to 130 = high average * ≥ = high

    Time frame: 36 months

  6. Cerebrospinal Fluid (CSF) biomarkers of AD

    correlate the new blood biomarkers levels and CSF biomarkers of AD (Aβamyloid, Tau, P Tau)

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 35 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2024
First posted
Sep 3, 2024
StartActual
Oct 31, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06582199
Collaborators
National Research Agency, France, Institut National de la Santé Et de la Recherche Médicale, France, Centre National de la Recherche Scientifique, France, URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Oct 31, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Olivier HANON, MD, PhD
Contact
olivier.hanon@aphp.fr
+ 1 44 08 33 81
Valérie PLENCE, MSc
Contact
valerie.plence@aphp.fr
+33 1 54 41 11 78
Emmanuel GOGNAT, MD, PhD
study director · Assistance Publique - Hôpitaux de Paris
Christian NERRI, PhD
study chair · Institut National de la Santé Et de la Recherche Médicale, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion